5 Key Takeaways

• 1

  A retrospective analysis of over 20,000 eyes treated for geographic atrophy (GA) identifies factors linked to treatment discontinuation.

• 2

  Baseline characteristics such as coexisting neovascular AMD and poor visual acuity are associated with early discontinuation of therapy.

• 3

  Discontinuation rates for intravitreal complement inhibitors increase over time, regardless of the treatment agent used.

• 4

  The study highlights the challenges retina specialists face in maintaining long-term compliance with GA therapies.

• 5

  Further longitudinal analysis is needed to clarify specific causes behind treatment discontinuation in GA patients.